Article information
Full text is only aviable in PDF
Bibliografia / Bibliography
[1.]
American Thoracic Society Documents.
Guidelines for the Management of Adults with Hospital-acquired, Ventilator-associated, and Healthcare-associated pneumonia.
Am J Respir Crit Care Med, 171 (2005), pp. 388-416
[2.]
M.J. Richards, J.R. Edwards, D.H. Culver, R.P. Gaynes.
Nosocomial Infections Surveillance System.
Crit Care Med, 27 (1999), pp. 887-892
[3.]
G. Campbell, M. Niederman, W. Broughton, D. Craven, A. Fein, M. Fink, et al.
Hospital-acquired pneumonia in adults: diagnosis, assessment of severity, initial antimi-crobial therapy, and preventive strategies. A consensus statement, American Thoracic Society.
Am J Respir Crit Care Med, 153 (1996), pp. 1711-1725
[4.]
J. Rello, J.A. Paiva, J. Baraibar, F. Barcenilla, M. Bodi, D. Castander, H. Correa, E. Diaz, J. Garnacho, M. Llorio, M. Rios, A. Rodriguez.
Solé-Violan.
International Conference for the Development of Consensus on the Diagnosis and Treatment of Ventilator-Associated Pneumonia. Chest, 120 (2001), pp. 955-970
[5.]
R. Jordà, A. Torres, F.J. Ariza, F. Álvarez-Lerma, F. Barcenilla, et al.
Recomendaciones para el tratamiento de la pneumonia intrahospitalaria grave.
Arch Bronconeumol, 40 (2004), pp. 518-533
[6.]
J. Chastre, J.Y. Fagon.
Ventilator-associated pneumonia.
Am J Respir Crit Care Med, 165 (2002), pp. 867-903
[7.]
A. Torres, R. Aznar, J.M. Gatell, et al.
Incidence, risk, and prognosis factores of nosocomial pneumonia in mechanically ventilated patients.
Am Rev Respir Dis, 142 (1990), pp. 523-528
[8.]
J. Rello, D.A. Ollendorf, G. Oster, V. Montserrat, L. Bellm, R. Redman, M.R. Kollef.
Epidemiology and outcomes of ventilator-associated pneumonia in a large US data-base.
Chest, 122 (2002), pp. 2115-2121
[9.]
D.K. Heyland, D.J. Cook, L. Griffith, et al.
The attributa-ble morbidity and mortality of ventilator-associated pneumonia in the critical ill patient.
Am J Respir Crit Care Med, 159 (1999), pp. 1249-1256
[10.]
A.A. El Solh, P. Sikka, F. Ramadan, J. Davies.
Etiology of severe pneumonia in the very elderly.
Am J Respir Crit Care Med, 163 (2001), pp. 645-651
[11.]
A.A. El Solh, A.T. Aquilina, R.S. Dhillon, F. Ramadan, P. Nowak, J. Davies.
Impact of invasive strategy on management of antimicrobial treatment failure in institutionalized older people with severe pneumonia.
Am J Respir Crit Care Med, 166 (2002), pp. 1038-1043
[12.]
N. Fabregas, S. Ewig, A. Torres, et al.
Clinical diagnosis of ventilator associated pneumonia revisited: comparative evaluation usind immediate post moprtem biopsies.
Thorax, 54 (1999), pp. 867-873
[13.]
C. Delclaux, E. Roupie, F. Blot, L. Brochard, F. Lemaire, C. Brun-Buisson.
Lower respiratory tract colonization and infection during severe acute respiratory distress syndrome: incidence and diagnosis.
Am J Respir Crit Care Med., 156 (1997), pp. 1092-1098
[14.]
C.M. Luna, P. Vujacich, M.S. Niederman, C. Vay, C. Ghe-rardi, J. Matera, E.C. Jolly.
Impact of BAL data on the therapy and outcome of ventilator-associated pneumonia.
Chest, 111 (1997), pp. 676-685
[15.]
M. Iregui, S. Ward, G. Sherman, V.J. Fraser, M.H. Kollef.
Clinical importance of delays in the initiation of appropriate antibiotic treatment for ventilator-associated pneu-monia.
Chest, 122 (2002), pp. 262-268
[16.]
F. Alvarez-Lerma.
Modification of empiric antibiotic treatment in patients with pneumonia acquired in the intensive care unit. ICU-Acquired Pneumonia Study Group.
Intensive Care Med, 22 (1996), pp. 387-394
[17.]
J.Y. Fagon, J. Chastre, M. Wolff, C. Gervais, S. Parer-Aubas, F. Stephan, T. Similowski, A. Mercat, J.L. Diehl, J.P. Sollet, A. Tenaillon.
Invasive and noninvasive strategies for management of suspected ventilator-associated pneumonia. A randomized trial.
Ann Intern Med, 132 (2000), pp. 621-630
[18.]
J. Chastre, M. Wolff, J.Y. Fagon, S. Chevret, F. Thomas, D. Wermert, E. Clementi, J. Gonzalez, D. Jusserand, P. Asfar, D. Perrin, F. Fieux, S. Aubas.
PneumA Trial Group: Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial.
JAMA., 290 (2003), pp. 2588-2598
[19.]
D.K. Heyland, D.J. Cook, J. Marshall, M. Heule, B. Guslits, J. Lang, R. Jaeschke.
The clinical utility of invasive diagnostic techniques in the setting of ventilator-associated pneumonia. Canadian Critical Care Trials Group.
Chest, 115 (1999), pp. 1076-1084
[20.]
S.H. Kirtland, D.E. Corley, R.H. Winterbauer, S.C. Spring-meyer, K.R. Casey, N.B. Hampson, D.F. Dreis.
The diagnosis of ventilator-associated pneumonia: a comparison of histologic, microbiologic, and clinical criteria.
Chest, 112 (1997), pp. 445-457
[21.]
D. Wermert, C.H. Marquette, M.C. Copin, F. Wallet, A. Fraticelli, P. Ramon, A.B. Tonnel.
Influence of pulmonary bacteriology and histology on the yield of diagnostic procedures in ventilator-acquired pneumonia.
Am J Respir Crit Care Med, 158 (1998), pp. 139-147
[22.]
J.J. Rouby, E. Martin De Lassale, P. Poete, M.H. Nicolas, L. Bodin, V. Jarlier, Y. Le Charpentier, J. Grosset, P. Viars.
Noso-comial bronchopneumonia in the critically ill. Histologic and bacteriologic aspects.
Am Rev Respir Dis, 146 (1992), pp. 1059-1066
[23.]
J. Pugin, R. Auckenthaler, N. Mili, et al.
Diagnosis of ventilator-associated pneumonia by bacteriologic analy- sis of bronchoscopic and non-bronchoscopic “blind” bronchoalveolar lavage fluid.
Am Rev Respir Dis, 143 (1991), pp. 1121-1129
[24.]
N. Singh, P. Rogers, C.W. Atwood, et al.
Short-course empiric antibiotic therapy for patients with pulmonary infiltrates in the intensive care unit: a proposed solution for indiscriminate antibiotic prescription.
Am J Respir Crit Care Med, 162 (2000), pp. 505-511
[25.]
C.M. Luna, D. Blanzaco, M.S. Niederman, et al.
Resolution of ventilator-associated pneumonia: Prospective evaluation of the clinical pulmonary infection score as an early clinical predictor of outcome.
Crit Care Med, 31 (2003), pp. 676-682
[26.]
M. Fartoukh, B. Maître, S. Honoré, et al.
Diagnosing pneumonia during mechanical ventilation. The Clinical Pulmonary Infection Score Revisited.
Am J Respir Crit Care Med, 168 (2003), pp. 173-179
[27.]
L. Papazian, P. Thomas, L. Garbe, et al.
Bronchoscopic or blind sampling techniques for the diagnosis of ventilator-associated pneumonia.
Am J Resp Crit Care Med, 152 (1995), pp. 1982-1991
[28.]
C. Franklin, et al.
Reduced mortality of pneumococcal bacteremia after early intensive care.
J Intensive Care, 6 (1994), pp. 302-307
[29.]
M. Niederman.
Gram-negative colonization of the respiratory tract: pathogenesis and clinical consequences.
Semin Respir Infect, 5 (1990 Sep), pp. 173-184
[30.]
J. Hayon, C. Figliolini, A. Combes, J.L. Trouillet, N. Kassis, M.C. Dombret, C. Gibert, J. Chastre.
Role of serial routine microbiologic culture results in the initial management of ventilator-associated pneumonia.
Am J Respir Crit Care Med, 165 (2002), pp. 41-46
[31.]
E.R.S. Task.
Force. Ventilator-associated pneumonia.
Eur Respir J, 17 (2001), pp. 1034-1045
[32.]
C. Luna, A. Videla, J. Mattera, et al.
Blood cultures have limited value in predicting severity of illness and as a diagnostic tool in ventilator-associated pneumonia.
Chest, 116 (1999), pp. 1075-1084
[33.]
O.C. Tablan, et al.
Guidelines for preventing health-care-associated pneumonia: recomendations of the CDC and the Health-care Infection Control Practices Advisory Committee.
MMWR Recomm Rep, 53 (2004), pp. 10-13
[34.]
M.H. Kollef, G. Sherman, S. Ward, et al.
Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients.
Chest, 115 (1999), pp. 462-474
[35.]
M. Kollef, S. Ward.
The Influence of Mini-BAL Cultures on Patient Outcomes, Implications for the Antibiotic Management of Ventilator-Associated Pneumonia.
Chest, 113 (1998), pp. 412-420
[36.]
M. Weinstein, M. Towns, S. Quartey, et al.
The Clinical Significance of Positive Blood Cultures in the 1990s: A Prospective Comprehensive Evaluation of the Micro-biology, Epidemiology, and Outcome of Bacteremia and Fungemia in Adults.
CID, 24 (1997), pp. 584-602
[37.]
P.D. Paepe, F.M. Belpaire, W.A. Buylaert.
Pharmacokinetic and pharmacodynamic considerations when treating patients with sepsis and septic shock.
Clin Pharma-cokinet, 41 (2002), pp. 1135-1151
[38.]
J.G. Pereira.
Antibioterapia na pneumonia: A emer-gência das resistências.
Revista de Infecções Respiratórias, 1 (2005), pp. 4-12
[39.]
E.H. Ibrahim, S. Ward, G. Sherman, R. Schaiff, V.J. Fraser, M.H. Kollef.
Experience with a clinical guideline for the treatment of ventilator associated pneumonia.
Crit Care Med, 29 (2001), pp. 1109-1115
[40.]
B. Sieger, S.J. Berman, R. Geckler, S. Farkas.
Empiric treatment of hospital-acquired lower respiratory tract infections with meropenem or ceftazidime with to-bramycin: A randomized study.
Crit Care Med, 25 (1997), pp. 1663-1670
[41.]
J. Rello, L. Vidaur, A. Sandiumenge, et al.
De-escalation therapy in ventilator-associated pneumonia.
Crit Care Med, 32 (2004), pp. 2183-2190
[42.]
S.T. Micek, S. Ward, V.J. Fraser, M.H. Kollef.
A randomized controlled trial of an antibiotic discontinuation policy for clinically suspected ventilator-associated pneu-monia.
Chest, 125 (2004), pp. 1791-1799
[43.]
M.R. Jacobs.
Optimisation of antimicrobial therapy using pharmacokinetic and pharmacodynamic parameters.
Clin Microbiol Infect, 7 (2001), pp. 589-596
[44.]
D. Andes, J. Anon, M.R. Jacobs, W.A. Craig.
Application of pharmacokinetics and pharmacodynamics to antimi-crobial therapy of respiratory tract infections.
Clin Lab Med, 24 (2004), pp. 477-502
[45.]
W.A. Craig.
Basic pharmacodynamics of antibacterials with clinical applications to the use of b-lactams, glycopeptides, and linezolid.
Infect Dis Clin N Am, 17 (2003), pp. 479-501
[46.]
C.M. Isada, B.L. Kasten, M.P. Goldman, L.D. Gray, J.A. Aberg.
Infectious diseases handbook, 5th edition,
[47.]
J.G. Pereira.
Antibióticos em perfusão contínua.
Revista Portuguesa de Medicina Intensiva, 13 (2004), pp. 15-19
[48.]
K. Leder, J.D. Turnidge, T.M. Korman, M.L. Grayson.
The clinical efficacy of continuous-infusion flucloxacil-lin in serious staphylococcal sepsis.
Journal of Antimi-crobial Chemotherapy, 43 (1999), pp. 113-118
[49.]
E.M. Grant, J.L. Kuti, D.P. Nicolau, C. Nightingale, R. Quin-tiliani.
Clinical efficacy and pharmacoeconomics of a continuous-infusion piperacillin-tazobactam program in a large community teaching hospital.
Pharmacotherapy, 22 (2002), pp. 471-483
[50.]
J. Lipmana, C.D. Gomersallb, T. Ginc, G.M. Joyntb, R.J. Youngb.
Continuous infusion ceftazidime in intensive care: a randomized controlled trial.
J Antimicrobial Chemotherapy, 43 (1999), pp. 309-311
[51.]
G.M. Joynt, J. Lipman, C.D. Gomersall, R.J. Young, E.L.Y. Wong, T. Gin.
The pharmacokinetics of once-daily dosing of ceftriaxone in critically ill patients.
J Antimicrobial Chemotherapy, 47 (2001), pp. 421-429
[52.]
J. Lipman, S.C. Wallis, C. Rickard.
Low plasma cefepime levels in critically ill septic patients: Pharmacokinetic modeling indicates improved troughs with revised dosing.
Antimicrob Agent Chemother, 43 (1999), pp. 2559-2561
[53.]
J. Li, R. Nation, J. Turnidge, R. Milne, et al.
Colistin: the reemerging antibiotic for multidrug-resistant Gram-negative bacterial infections.
Lancet Infect Dis, 6 (2006), pp. 589-601
[54.]
J. Turnidge.
Pharmacodynamics and dosing of ami-noglycosides.
Infect Dis Clin N Am, 17 (2003), pp. 503-528
[55.]
E.D. Hermsen, C.J. Sullivan, J.C. Rotschafer.
Polymyxins: Pharmacology, pharmacokinetics, pharmacodynamics, and clinical applications.
Infect Dis Clin N Am, 17 (2003), pp. 54562
[56.]
J. Li, J. Turnidge, R. Milne, R.L. Nation, K. Coulthard.
In vitro pharmacodynamic properties of Colistin and Colistin Methanesulfonate against Pseudomonas aeruginosa iso-lates from patients with cystic fibrosis.
Antimicrob Agent Chemother, 45 (2001), pp. 781-785
[57.]
D.L. Wyncoll, R. Bowry, L.J. Giles.
Antibiotics in continuous infusion: Time for re-evaluation?.
Year Book of Intensive Care and Emergency Medicine, pp. 398-406
[58.]
J. Rello, V. Ausina, et al.
Impact of previous antimicrobial therapy on the etiology and outcome of ventilator-associated pneumonia.
Chest, 104 (1993), pp. 1230-1235
[59.]
J.L. Trouillet, J. Chastre, A. Vuagnat, et al.
Ventilator-associated pneumonia caused by potentially drug-resistant bacteria.
Am J Respir Crit Care Med, 157 (1998), pp. 531-539
[60.]
J.Y. Fagon, J. Chastre, Y. Domart, et al.
Nosocomial pneumonia in patients receiving continuous mechanical ventilation: prospective analysis of 52 episodes with use of a protected specimen brush and quantitative culture techniques.
Am Rev Respir Dis, 139 (1989), pp. 877-884
[61.]
J. Rello, E. Quintana, V. Ausina, et al.
Incidence, etiology and outcome of nosocomial pneumonia in mechanically ventilated patients.
Chest, 100 (1991), pp. 439-444
[62.]
S.C. Brewer, R.G. Wunderink, C.B. Jones, et al.
Ventila-tor-associated pneumonia due to Pseudomonas aeruginosa.
Chest, 109 (1996), pp. 1019-1029
[63.]
O. Leroy, S. Jaffré, T. d’Ecrivan, et al.
Hospital-Acquired Pneumonia. Risk factors for antimicrobial-resistant causative pathogens in critically ill patients.
Chest, 123 (2003), pp. 2034-2042
[64.]
R.T. Sadikot, T.S. Blackwell, J.W. Christman, et al.
Pathogen-host interaction in Pseudominas aeruginosa Pneumonia.
Am J Respir Crit Care Med., 171 (2005), pp. 1209-1223
[65.]
I. Chatzinikoloau, D. Abi-Said, G.P. Bodey, et al.
Recent experience with Pseudomonas aeruginosa bacteremia in patients with cancer: retrospective analysis of 24 episodes.
Arch Intern Med, 160 (2000), pp. 501-509
[66.]
J. Chastre, J.L. Trouillet.
Problem pathogens Pseudomonas aeruginosa and Acinetobacter.
Semin Respire Infect, 15 (2000), pp. 287-298
[67.]
F. Vidal, J. Mens, J.A. Martinez, et al.
Pseudomonas aeruginosa bacteremia in patients infected with HIV-1.
Eur J Clin Microbiol Infect Dis, 18 (1999), pp. 473-477
[68.]
J. Rello, V. Ausina, M. Ricart, et al.
Risk factors for infection by Pseudomonas aeruginosa in patients with ventilator-associated pneumonia.
Intensive Care Med, 20 (1994), pp. 193-198
[69.]
N. Sopena, M. Sabria, M.L. Pedro-Botet, et al.
Prospective study of community-acquired pneumonia of bacterial etiology in adults.
Eur J Clin Microbiol Infect Dis, 18 (1999), pp. 852-858
[70.]
F. Aranciba, T.T. Bauer, S. Ewig, et al.
Community-acquired pneumonia due to gram-negative bacteria and Pseu-domonas aeruginosa.
Arch Intern Med, 162 (2002), pp. 1849-1858
[71.]
K.H. Groenewegen, et al.
Bacterial infections in patients requiring admission for an acute exacerbation of COPD; a 1-year prospective study.
Respir Med, 97 (2003), pp. 770-777
[72.]
S. Nseir, C. Pompeo, S. Soubrier, et al.
Impact of Ventilator-associated pneumonia on outcome in patients with COPD.
Chest, 128 (2005), pp. 1650-1656
[73.]
E.H. Ibrahim, S. Ward, G. Sherman, et al.
A comparative analysis of patients with early-onset versus late-onset nosoco-mial pneumonia in the ICU setting.
Chest, 117 (2000), pp. 1434-1442
[74.]
J. Rello, M. Sa-Borges, H. Correa, S.R. Leal, J. Baraibar.
Variations in etiology of ventilator-associated pneumo-nia across four treatment sites: implications for antimi-crobial prescribing practices.
Am J Respir Crit Care Med, 160 (1999), pp. 608-613
[75.]
E.H. Ibrahim, G. Sherman, S. Ward, et al.
The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting.
Chest, 118 (2000), pp. 146-155
[76.]
J. Rello, A. Torres, M. Ricart, et al.
Ventilator-associated pneumonia by Staphylococcus aureus. Comparison of methicillin-resistant and methicillin-sensitive episodes.
Am J Respir Crit Care Med, 150 (1994), pp. 1545-1549
[77.]
J. Rello, E. Quintana, V. Ausina, et al.
Risk factors for Staphylococcus aureus nosocomial pneumonia in critically ill patients.
Am Rev Respir Dis, 142 (1990), pp. 1320-1324
[78.]
J.S. Solomkin, H.S. Bjornson, M. Cainzos, et al.
A consensus statement on empiric therapy for suspected gram-positive infections in surgical patients.
Am J Surgery, 187 (2004), pp. 134-145
[79.]
A. Vuagnat, R. Stern, A. Lotthe, et al.
High dose vancomycin for osteomyelitis: continuous vs. intermittent infusion.
Journal Clinical Pharmacy Therapeutics, 29 (2004), pp. 351-357
[80.]
J.M. Pereira, A. Azevedo, J.A. Paiva.
Continuous infusion of vancomycin: is it a step forward in vancomycin therapy?.
Intensive Care Med, 31 (2005), pp. S222
[81.]
M. Wysocki, F. Delatour, F. Faurisson, A. Rauss, et al.
Continuous versus intermittent infusion of vancomycin in severe staphylococcal infections: prospective multicenter randomized study.
Antimicrob Agents Chemother, 45 (2001), pp. 2460-2467
[82.]
J. Rello, J. Sole-Violan, M. Sa-Borges, J. Garnacho-Montero, et al.
Pneumonia caused by oxacillin-resistant Staphylococcus aureus treated with glycopeptides.
Crit Care Med, 33 (2005), pp. 1983-1987
[83.]
J. Garnacho-Montero, C. Ortiz-Leyva, F.J. Jiménez-Jimé-nez, et al.
Treatment of multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia (VAP) with intravenous colistin: A comparision with imipenem-sus-ceptible VAP.
Clin Infect Dis, 36 (2003), pp. 1111-1118
[84.]
J. Baraibar, H. Correa, D. Mariscal, et al.
Risk factors for infection by Acinetobacter baumannii in intubated patients with nosocomial pneumonia.
Chest, 112 (1997), pp. 1050-1054
[85.]
S. Mahgoub, et al.
Underlying characteristics of patients harbouring higly resistant Acinetobacter baumannii.
Am J Infect Control, 30 (2002), pp. 386-390
[86.]
Rodriguez-Baño, et al.
Clinical features and epidemiology of Acinetobacter baumannii colonization and infection in Spanish hospitals.
Infect Control Hosp Epidemiol, (2004), pp. 825-831
[87.]
M. Ayan, et al.
Bacteriological, clinical and epidemiological characteristics of hospital-acquired Acinetobacter infection in a teaching hospital.
J Infect, 54 (2003), pp. 39-45
[88.]
D. Villers, E. Espaze, M. Coste-Burel, et al.
Nosoco-mial Acinetobacter baumannii infections: microbiological and clinical epidemiology.
Ann Intern Med, 129 (1998), pp. 182-189
[89.]
X. Corbella, M. Pujol, J. Ayats, et al.
Relevance of digestive tract colonization in the epidemiology of nosocomial infections due to multiresistant Acinetobacter bau-mannii.
Clin Infect Dis, 23 (1996), pp. 329-334
[90.]
O. Lortholary, J.-Y. Fagon, A.B. Hoi, et al.
Nosocomial acquisition of multiresistant Acinetobacter baumannii: risk factors and prognosis.
Clin Infect Dis, 20 (1995), pp. 790-796
[91.]
O.C. Tablan, et al.
Guidelines for preventing health-care-associated pneumonia: recomendations of the CDC and the Health-care Infection Control Practices Advisory Committee.
MMWR Recomm Rep, 53 (2004), pp. 1-36
[92.]
M. Ebiary, X. Sarmiento, A. Torres, S. Nogue, E. Mesalles, M. Bodi, J. Almirall.
Prognostic factors of severe Legionella pneumonia requiring admission to ICU.
Am J Respir Crit Care Med, 156 (1997), pp. 1467-1472
[93.]
Ls Tkatch, S. Kusne, I. WD, et al.
Epidemiology of legionella pneumonia and factors associated with legio-nella-related mortality at a terciary care center.
Clin Infect Dis, 27 (1998), pp. 1479-1486
[94.]
J. Carratala, F. Gudiol, R. Pallares, et al.
Risk factors for nosocomial Legionella pneumophila pneumonia.
Am J Respir Crit Care Med, 149 (1994), pp. 625-629
[95.]
N.M. Le Saux, L. Sekla, J. McLeod, S. Parker, D. Rush, J.R. Jeffery, R.C. Brunham.
Epidemic of nosocomial Legionnai-res’ disease in renal transplant recipients: a case-control and environmental study.
Can Med Assoc J, 140 (1989), pp. 1047-1053
[96.]
V.L. Yu, et al.
Legionnaires disease: new clinical perspective from a prospective pneumonia study.
Am J Med, 73 (1982), pp. 357-361
[97.]
J. Stout, V.L. Yu, R.M. Vickers, J. Shonnard.
Potable water supply as the hospital reservoir for Pittsburgh pneu-monia agent.
Lancet, 1 (1982), pp. 471-472
[98.]
M. Sabria, M. Campins.
Legionnaire’disease: update on epidemiology and management options.
Am J Respir Med, 2 (2003), pp. 235-243
[99.]
G.A. Ortolano, M.B. Mc Alister, J.A. Angelbeck, et al.
Hospital water point-of-use filtration: A complementary strategy to reduce the risk of nosocomial infection.
Am J Infect Control, 33 (2005), pp. S1-S19
[100.]
R.A. Venezia, M.D. Agresta, E.M. Hanley, K. Urquhart, D. Schoonmaker.
Nosocomial legionellosis associated with aspiration of nasogastric feedings diluted in tap water.
Infect Control Hosp Epidemiol, 15 (1994), pp. 529-533
[101.]
J. Darelid, S. Lofgren, B.E. Malmvall.
Control of nosocomial Legionnaires’ disease by keeping the circulating hot water temperature above 55 degrees C: experience from a 10-year surveillance programme in a district general hospital.
J Hosp Infect, 50 (2002), pp. 213-219
[102.]
M. Hilf, V.L. Yu, J. Sharp, et al.
Antibiotic therapy for Pseudomonas aeruginosa bacteremia: outcome correlations in a prospective study of 200 patients.
Am J Med, 87 (1989), pp. 540-546
[103.]
J.A. Korvick, C.S. Bryan, B. Farber, et al.
Prospective observational study of Klebsiella bacteremia in 230 patients: outcome for antibiotic combinations versus monotherapy.
Antimicrob Agents Chemother, 36 (1992), pp. 2639-2644
[104.]
A. Sandiumengue, E. Diaz, M. Bodi, J. Rello.
Therapy of ventilator-associated pneumonia- A patient-based approach based on the ten rules of “The Tarragona Strategy”.
Intensive Care Med., 29 (2003), pp. 876-883
[105.]
R.G. Wunderink, J. Rello, S.K. Cammarata, R.V. Croos-Da-brera, M. Kollef.
Linezolid vs vancomycin: analysis of two double-blind studies of patients with methicillin-resistant staphylococcus aureus nosocomial pneumonia.
Chest, 124 (2003), pp. 1789-1797
[106.]
C.M. Lee, H.K. Lin, C.P. Liu, et al.
Treatment of pan-drug resistant Acinetobacter baumannii.
Scand J Infect Dis, 37 (2005), pp. 195-199
[107.]
P.K. Linden, D.L. Paterson.
Parenteral and inhaled colistin fortreatment of ventilator-associated pneumonia.
Clin Infect Dis, 43 (2006), pp. S89-S94
[108.]
A. Montero, Ariza, X. Corballa, et al.
Antibiotic combinations for serious infections caused by carbapenem-resistant Acinetobacter baumannii in a mouse pneumonia model.
J Antimicrob Chemother, 54 (2004), pp. 1085-1091
[109.]
J.M. Cisneros-Herreros, J. Garnacho-Montero, M.E. Pachon-Ibanez.
nosocomial pneumonia due to Acinetobacter bau-mannii.
Enferm Infecc Microbiol Clin, 23 (2005), pp. 46-51
[110.]
A. Michalopoulos, S.K. Kasiakou, Z. Mastora, et al.
Colistin for the treatment of nosocomial pneumonia due to multidrug-resistant Gram-negative bacteria in patients without cystic fibrosis.
Crit Care, 9 (2005), pp. R53-R59
[111.]
J.J. Rahal.
Novel antibiotic combinations against infections with almost completely resistant Pseudomonas ae-ruginosa and Acinetobacter Species.
Clin Infect Dis, 43 (2006), pp. S95-S99
[112.]
M.E. Falagas, S.K. Kasiakou, S. Tsiodras, et al.
The use of intravenous and aerosolized polymyxins for the treatment of infections in critically ill patients: a review of the recent literature.
Clin Med Res, 4 (2006), pp. 138-146
[113.]
M.L. Pedro-Botet, V. Yu.
Tratment and prevention of Legionella infection, (2006),
[114.]
E.N. Vergis, A. Indorf, T. File, et al.
Azithromycin vs cefuroxime plus erythromycin for empirical treatment of community-acquired pneumonia in hospitalized patients: a prospective, randomized, multicenter trial.
Arch Intern Med, 160 (2000), pp. 1294-1300
[115.]
R.M. Blazquez Garrido, F.J. Espinosa Parra, L. Frances, et al.
Antimicrobial chemotherapy for legionnaires disease: levofloxacin versus macrolides.
Clin Infect Dis, 40 (2005), pp. 800-806
[116.]
D. Gruson, G. Hilbert, F. Vargas, R. Valentino, C. Bebear, A. Allery, C. Bebear, G. Gbikpi-Benissan, J.P. Cardinaud.
Rotation and restricted use of antibiotics in a medical intensive care unit: impact on the incidence of ventilator-associated pneumonia caused by antibiotic resistant gram-negative bacteria.
Am J Respir Crit Care Med, 162 (2000), pp. 837-843
[117.]
M. Ferrer, M. Ioanas, A. Torres.
Evaluation of non-responding patients with ventilator-associated pneumonia.
Yearbook of Intensive Care and Emergency Medicine, pp. 365-375
[118.]
S. Lowenkron, A. Fein.
The 10 most common questions about non-resolving pneumonia.
Clin Pulm Med, 2 (1995), pp. 8897
[119.]
T. Kuru, J.P. Lynch 3rd..
Nonresolving or slowly resolving pneumonia.
Clin Chest Med, 20 (1999), pp. 623-651
[120.]
L. Rome, G. Murali, M. Lippmann.
Nonresolving pneumonia and mimics of pneumonia.
Med Clin North Am, 85 (2001), pp. 1511-1530
[121.]
J. Rello, D. Mariscal, F. March, et al.
Recurrent Pseudomonas aeruginosa pneumonia in ventilated patients: relapse or reinfection?.
Am J Respir Crit Care Med, 157 (1998), pp. 912-916
[122.]
D.R. Silver, I.L. Cohen, P.F. Weinberg.
Recurrent Pseu-domonas aeruginosa pneumonia in an intensive care unit.
Chest, 101 (1992), pp. 194-198
[123.]
S. Crouch Brewer, R.G. Wunderink, C.B. Jones, et al.
Ventilator-associated pneumonia due to Pseudomonas ae-ruginosa.
Chest, 109 (1996), pp. 1019-1029
[124.]
S. Rowe, W.G. Cheadle.
Complications of nosoco-mial pneumonia in the surgical patient.
Am J Surg, 179 (2000), pp. 63-68
[125.]
D. Craven.
Preventing ventilator –associated pneumonia in adults.
Chest, 130 (2006), pp. 251-260
[126.]
D.M. Berwick, D.R. Calkins, McCamnon, et al.
The 100.000 Lives Campaign: setting a goal and a deadline for improving health care quality.
JAMA, 295 (2006), pp. 324-327
[127.]
G. van den Berghe, P. Wouters, F. Weekers, et al.
Intensive insulin therapy in critically ill patients.
N Engl J Med, 345 (2001), pp. 1359-1367
Sociedade Portuguesa de Pneumologia e Sociedade Portuguesa de Cuidados Intensivos / Portuguese Society of Pulmonology and Intensive Care Society
O presente documento é simultaneamente publicado na Revista Portuguesa de Medicina Intensiva (2007; 14(1):7-30) / This work is published simultaneously in the Portuguese Journal of Intensive Care Medicine (2007; 14(1):7-30)
Copyright © 2007. Sociedade Portuguesa de Pneumologia/SPP
Open access
This work is licensed under a Creative Commons Attribution 4.0 International License.
Publish in
Pulmonology
Pulmonology
- Home
- All contents
- Publish your article
- About the journal
- Metrics
- Open access
Article options